What it sells
Breakthrough medicines unlocking the biology of heme
Business model breakdown
Trigger: what makes them buy now?
EPP/XLP have no approved disease-modifying treatments; patients suffer painful photosensitivity and liver damage.
Workflow: what inputs become what output?
Biologic that removes protoporphyrin IX from circulation (porphyrin scavenger) and heme-sequestering proteins; programs are preclinical.
Economics: what it saves and how it charges
UnverifiedPre-revenue biotech; value comes from developing drugs for diseases with no approved disease-modifying treatment.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2024 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.